A NOVEL DNA METHYLATION-BASED SURROGATE BIOMARKER FOR LATENT SYSTEMIC INFLAMMATION
2024

New DNA Test for Inflammation and Aging

publication Evidence: moderate

Author Information

Author(s): Meier Helen, Klopack Eric, Farina Mateo, Hernández Belinda, Mitchell Colter, Faul Jessica, McCrory Cathal, Crimmins Eileen

Primary Institution: Institute for Social Research, Michigan, United States

Hypothesis

Can a DNA methylation-based biomarker effectively predict chronic systemic inflammation and its associated health outcomes?

Conclusion

The InfLaMeS biomarker is a strong alternative to traditional blood tests for measuring inflammation and predicting health outcomes.

Supporting Evidence

  • The InfLaMeS biomarker correlates strongly with individual inflammation markers.
  • It performs similarly to traditional measures of systemic inflammation.
  • The study focused on predicting multimorbidity, disability, and mortality.

Takeaway

Scientists created a new DNA test that can help us understand how inflammation affects our health as we age.

Methodology

The study evaluated a DNA methylation surrogate biomarker against measured inflammatory biomarkers in predicting health outcomes.

Digital Object Identifier (DOI)

10.1093/geroni/igae098.4292

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication